

‘ENSURING DRUG SECURITY’ RUSSIAN PHARMACEUTICAL FORUM PROGRAMME

June 5, 2024, St. Petersburg

Programme accurate as at June 11, 2024

June 5, 2024

10:00–11:30

Congress Centre
zone B, 2nd floor,
conference hall B1

‘Ensuring Drug Security’ Russian Pharmaceutical Forum

Looking Into the Future Today. Pharma 2030 and the Long-Term Planning Course

In partnership with the Association of Pharmaceutical Manufacturers of the Eurasian Economic Union (EAEU)

Russia has completed the first year of its Pharma-2030 strategy for the development of the pharmaceutical industry. According to the DSM Group, the size of the Russian pharmaceutical market increased to RUB 2.578 trillion in 2023. The Strategy Implementation Plan approved by the Russian government includes a wide range of measures to support the pharmaceutical industry with thorough planning for the next three years. However, the Long and Active Life national project that has been announced extends the planning horizon until 2030 due to the continued implementation and funding of federal projects to combat diabetes as well as cardiovascular, oncological, and infectious diseases. The government and business need to analyse the initial results and come up with proposals to modernize the Strategy, improve the drug regulation system, and update tools to support domestic pharmaceuticals, including innovative developments and the production of active pharmaceutical substances and ingredients for their creation. Russia must find ways to introduce innovative solutions, achieve technological sovereignty, and increase the share of domestic medicines. What results have the first year of the Strategy produced? What different approaches are needed due to the expanded planning horizon? What qualitative changes are crucial for the successful implementation of the country’s federal projects? Which unified coordinate system should be selected to predict the healthcare system’s demand for drugs? What are the most effective measures to support the pharmaceutical industry

Moderator:

- **Aleksey Kedrin**, Chairman of the Board, Association of Pharmaceutical Manufacturers of the Eurasian Economic Union (EAEU)

Panellists:

- **Elena Astapenko**, Director, Department of Pharmaceutical Provision and Regulation of the Circulation of Medical Devices, Ministry of Health of the Russian Federation
- **Vilena Galkina**, Director for Relations with Government Authorities, Geropharm LLC
- **Andrey Ivaschenko**, Chairman of the Board of Directors, ChemRar Group of Companies
- **Dmitry Kudlay**, Vice President for the Introduction of New Medical Technologies, Generium
- **Yevgeni Nifantiev**, Deputy Chairman of the State Duma Committee of the Federal Assembly of the Russian Federation of the Health Protection Committee
- **Timofey Nizhegorodtsev**, Deputy Head, Federal Antimonopoly Service of the Russian Federation
- **Ekaterina Priezzheva**, Deputy Minister of Industry and Trade of the Russian Federation
- **Lyudmila Scherbakova**, President, Velfarm Group of Companies
- **Aleksandr Semenov**, President, Active Component
- **Evgeniya Shapiro**, Director General, PSK Pharma
- **Dmitry Zaitsev**, General Director, Pharmstandard

Front row participant:

- **Victoria Galkovskaya**, Deputy Head, The Federal Service for Intellectual Property (Rospatent)

10:00–11:30

Congress Centre
zone A, 3rd floor,
conference hall A

‘Ensuring Drug Security’ Russian Pharmaceutical Forum

Obesity: The Global Epidemic of the 21st Century?

In partnership with GEROPHARM

Today, there are more than a billion people around the world living with obesity, 159 million of whom are children, and this figure is constantly trending upward. The situation in Russia is consistent with global trends: more than 45 million of the country’s residents suffer from obesity. Roughly 10% of them are

morbidly obese, while more than 30% are overweight, and the number of such people increase each year. Problems with excess weight lead to the development of dangerous conditions and non-communicable diseases, including cardiovascular diseases, which are the main cause of death around the world: heart attack, stroke, diabetes, oncology, and diminished reproductive functions. Excess weight is not only an aesthetic problem, but a serious metabolic disorder, a source of increased risk of premature death, and a real threat to the health of the nation, which, in turn, causes economic and social damage to the state. However, doctors do not always pay proper attention to the treatment of obesity, as they take it as a whole with other diseases instead of viewing it as a separate disease. How can we change the attitude towards the problem of obesity among the medical community? How can we promote knowledge about a healthy lifestyle and the prevention of excess weight among the population? Why should obesity be recognized as a socially significant disease? What innovative approaches to the treatment of excess body weight exist today?

Moderator:

- **Marina Rykova**, Editor-in-Chief, Stroynee.pro

Panellists:

- **Oksana Drapkina**, Director, National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
- **Evgeny Kamkin**, Deputy Minister of Health of the Russian Federation
- **Arina Kiseleva**, Semi-finalist of the Big Girls Show
- **Natalia Mokrysheva**, Director, Head of the Department of Personalized and Translational Medicine, National Medical Research Center of Endocrinology, Ministry of Health of the Russian Federation; Corresponding Member of the Russian Academy of Sciences
- **Petr Rodionov**, Deputy Chairman of the Council under the Government of the Russian Federation for Trusteeship in the Social Sphere
- **Olga Starikova**, Head of National Project Support Division, Natsionalnye Prioritety
- **Yury Zhulev**, President, Russian Hemophilia Society

10:00–11:30

Congress Centre
zone B, 2nd floor,
conference hall B3

'Ensuring Drug Security' Russian Pharmaceutical Forum

The Future of Diagnosing and Treating Autoimmune Diseases

Autoimmune diseases remain one of the biggest challenges in the medical world and pose a serious burden for the economy due to the high risk of disability and the poor prognosis for patients. Epidemiological studies show that the most common autoimmune disease is type 1 diabetes, which generally appears in childhood. At present, the causative factor of autoimmune diseases is only known in isolated cases, and most treatment strategies simply aim to contain symptoms and complications. The scientific and medical knowledge that has been gained in such areas as immunology and genetically engineered biological and cell therapy is now bringing scientists closer to understanding the causes of autoimmune destruction, which will make it possible to correctly verify the diagnosis and find fundamentally new therapeutic approaches to the effective treatment of a wide range of autoimmune diseases. How are innovative discoveries in autoimmunology changing the face of pharmacotherapy for autoimmune diseases today? What opportunities does personalized medicine offer for the diagnosis and treatment of autoimmune diseases? Can breakthrough solutions in the treatment of autoimmune diseases be integrated into practical healthcare? How close is medical science to understanding the causes of type 1 diabetes, which threatens children's health?

Moderator:

- **Evelina Zakamskaya**, TV Presenter, Russia 24 TV Channel; Chief Editor, Doctor TV Channel

Panellists:

- **Aleksandr Lila**, Director, V.A. Nasonova Research Institute of Rheumatology; Chief Freelance Specialist Rheumatologist of the Ministry of Health of the Russian Federation
- **Sergei Lukyanov**, Rector, N.I. Pirogov Russian National Research Medical University
- **Sara Qiu**, Managing Director, Syai
- **Kirill Rodin**, Director for Work with Public Authorities, All-Russian Public Opinion Research Center

Front row participants:

- **Gagik Galstyan**, President, Russian Diabetes Association
- **Yury Glukhov**, General Director, ELTA Company
- **Musa Khaitov**, Director, National Research Center – Institute of Immunology of the FMBA of Russia
- **Tamara Kozyreva**, Director, ANO "Agency for the Development of Initiatives in the Field of Health Care"; head of the "Help to the First" project
- **Elena Petryaykina**, Director, Russian Children's Clinical Hospital – Branch of N.I. Pirogov National Medical and Surgical Center of the Ministry of Health of the Russian Federation (online)

10:00–11:30

Congress Centre
zone B, 2nd floor,
conference hall B4

'Ensuring Drug Security' Russian Pharmaceutical Forum

New Approaches to Drug Circulation

The challenges Russia has faced in recent years have shown that the development, registration, and commercialization of medicines can be significantly accelerated without compromising safety and quality. This experience is being actively used today. Regulatory changes are not only taking place in Russia, but throughout the entire Eurasian Economic Union. The general processes associated with the circulation of drugs are functioning and continue to be refined. A system to monitor the movement of medicines has been introduced, which makes it possible to control the supply of drugs, verify the availability of medicines in the regions, track the journey of products from the manufacturing plant to the pharmacy and the hospital, and guarantee its authenticity. Another important aspect is the growth of e-commerce in the drug market and the need for comprehensive control to prevent the threat of illegal sales of drugs to the public. The supervisory authorities continue to focus on the quality and safety of medical care in primary healthcare and whether drug prescriptions are provided in accordance with clinical recommendations. What advantages does a unified market for drugs provide for all participants in the pharmaceutical market? What prospects exist for the development and use of a system to monitor the movement of medicines? How is transparency and safety ensured in the online pharmaceuticals sector and what prospects does it offer for patient comfort? What is the role of drug therapy in clinical guidelines? Would the standardization of processes affect the quality of medical care?

Moderator:

- **Alla Samoylova**, Head, Federal Service for Surveillance in Healthcare (Roszdravnadzor)

Panellists:

- **Dmitry Alkhazov**, Chief Executive Officer, Advanced Technologies Development Center (ATDC)
- **Dmitriy Galkin**, Director of Department of Pharmaceutical and Medical Industry Development, Ministry of Industry and Trade of the Russian Federation
- **Sergey Glagolev**, Deputy Minister of Health of the Russian Federation
- **Guvenc Kockaya**, General Director, Econix Research, Analysis and Consulting Inc.
- **Vitaliy Omelyanovskiy**, General Director, Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation
- **Aleksandr Petrov**, Deputy, member of the State Duma Committee on Health Protection of the Federal Assembly of the Russian Federation
- **Andrey Sarana**, First Deputy Chairman of the Health Committee of St. Petersburg

Front row participants:

- **Victor Dmitriev**, General Manager, Association of Russian Pharmaceutical Manufacturers; Chairman of the Public Council under the Federal Service for Surveillance in Healthcare
- **Vasily Ignatiev**, General Director, R-Pharm

12:15–13:45

Congress Centre
zone D, conference hall
D1

'Ensuring Drug Security' Russian Pharmaceutical Forum

Plenary session

Drug Security in BRICS Countries

Ensuring access to effective and high-quality drugs for patients is one of the top priorities on the drug security agenda in the expanded BRICS region. The main focuses of cooperation among BRICS nations are: biosafety issues; strengthening capacity for the development and production of vaccines; increasing the size of national drug markets and the overall share of BRICS markets in the global context; finding a balance between medicinal sovereignty and the unimpeded mutual supplies of drugs; expanding cooperation in pharmaceutical innovations; combining production and research capabilities; and optimizing regulatory procedures to simplify market access for safe and high-quality biosimilars amidst fair competition and in people's interests. Given the current level of geopolitical turbulence today, the drug policies of BRICS member countries should focus on developing long-term partnerships. Does the pharmaceutical market of BRICS countries have the potential and effective solutions that will help address the new challenges? How should BRICS states interact to ensure drug security for their citizens? What mechanisms are needed to harmonize this process? What prospects are there for BRICS countries to collaborate on their drug policies?

Moderator:

- **Aleksey Ivanov**, Director, HSE – Skolkovo Institute for Law and Development, International BRICS Competition Law and Policy Centre, National Research University Higher School of Economics

Panellists:

- **Mikhail Murashko**, Minister of Health of the Russian Federation
- **Irina Panarina**, General Manager, AstraZeneca Russia and Eurasia

- **Daniel Pereira**, Director, Brazilian Health Regulatory Agency
- **Aleksandr Petrov**, Deputy, member of the State Duma Committee on Health Protection of the Federal Assembly of the Russian Federation
- **Ekaterina Priezzheva**, Deputy Minister of Industry and Trade of the Russian Federation
- **Evgeniya Shapiro**, Director General, PSK Pharma
- **Prann Sharma**, Executive Director, BRICS Chamber of Commerce and Industry
- **Tatyana Yakovleva**, First Deputy Head, Federal Medical-Biological Agency of the Russian Federation

Front row participant:

- **Alexandre Cordeiro Macedo**, President, Administrative Council for Economic Defense of the Federative Republic of Brazil

14:30–16:00Congress Centre
zone A, 3rd floor,
conference hall A

'Ensuring Drug Security' Russian Pharmaceutical Forum

Innovative Pharmaceuticals on the Path to Progress. What is the Best Way to Stimulate the Industry's Development?

The pharmaceutical industry is one of the most rapidly developing sectors of the Russian economy. In the current times, pharmaceuticals manufacturers, particularly high-tech Russian companies or 'national champions' as they are called, have become the main driving force in the development of innovative Russian pharmaceuticals due to their substantial investments in research and development and solid performance during the COVID-19 pandemic and success in implementing priority import substitution projects. However, the further development of the industry still hinges on improved measures for the funding of new developments and tools to provide government support to pharmaceutical companies. Grants, concessional loans, equity investments, and public listings are all effective funding tools that could be used to develop cutting-edge projects in the pharmaceutical industry, which would improve business efficiency and potentially reduce innovation costs. What are some of the best domestic and international practices and cases that exist today for funding pharmaceutical innovations? How will digital financial assets and investment platforms help the Russian pharmaceutical sector generate additional investment for development? How can we enhance the appeal of pharmaceutical companies and reduce risks for investors? How should we fund the 'valley of death' in the development of new drugs? What factors and mechanisms are crucial to building an innovative environment that will support an increase in the share of high-quality domestic drugs on the Russian market, including as part of the process of phasing out imports?

Moderator:

- **Vadim Tarasov**, Director, Institute of Translational Medicine and Biotechnology Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University

Panellists:

- **Oleg Astafurov**, Vice President of Government Relations, Pharmasintez Group of Companies
- **Pavel Dvornichenko**, General Director, Engineering and Innovations Support Center
- **Andrey Ivaschenko**, Chairman of the Board of Directors, ChemRar Group of Companies
- **Vadim Kukava**, Executive Director, The Association of Pharmaceutical Companies «Innovative Pharma»
- **Sergey Masyuk**, General Director, Artgen Biotech
- **Larisa Matveeva**, Executive Director, Association of International Pharmaceutical Manufacturers
- **Natalya Popova**, First Deputy General Director, Innopraktika
- **Tadzio Schilling**, Chief Executive Officer, Association of European Businesses (AEB)
- **Tatyana Semenova**, Deputy Minister of Health of the Russian Federation (**online**)
- **Oleg Tsetlin**, Director of the project office, VEB.RF

Front row participants:

- **Oleg Lavrov**, Advisor to the General Director, Innovative Engineering Center
- **Nadezhda Rukavitsyna**, Head of the Center for Support of Innovation Implementation, Center for Expertise and Quality Control of Medical Care of the Ministry of Health of the Russian Federation

14:30–16:00Congress Centre
zone B, 2nd floor,
conference hall B1

'Ensuring Drug Security' Russian Pharmaceutical Forum

Women in Pharmaceuticals and Healthcare. Working Together for a Healthy Society

Women play a major role in the healthcare system and make significant contributions to the implementation of national policies in the public's interest. They are introducing new effective models for the healthcare system and account for a substantial majority of doctors and medical workers (according

to the Russian Ministry of Health, women make up 70.8% of the total number of doctors in Russia, 94.5% of paramedical workers, and 63% of pharmaceutical industry workers). In all regions of Russia, women are also implementing their own public health projects to promote a healthy lifestyle, knowledge about ways for people to protect their health, as well as public health awareness. Women leaders need to systematically unite to promote the health agenda with support from the government and society. What role do women play in the development of the medical care system in Russia, and what support do representatives of the professional medical community need? What is women's role in the development of the pharmaceutical industry and ensuring the country's medicinal sovereignty? What opportunities are available to Russian women today to ensure their professional fulfilment in the healthcare and pharmaceutical industries, develop skills, and acquire new knowledge? What projects and tools could help bring women leaders together in the interests of protecting public health? What support measures are needed for the women's community to implement and promote projects and socially significant initiatives that aim to protect people's health?

Moderator:

- **Lyudmila Scherbakova**, President, Velfarm Group of Companies

Panellists:

- **Oksana Drapkina**, Director, National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
- **Alisa Dzhangiryants**, Deputy General Director for ensuring access of drugs to the market and oncology, Swix Healthcare LLC
- **Elvira Gilmanova**, Company Development Director, Genome Expert; Deputy General Director, BARS Group
- **Galina Karelova**, First Deputy Chairman of the Federation Council Committee of the Federal Assembly of the Russian Federation on Federal Structure, Regional Policy, Local Self-Government and Northern Affairs
- **Valentina Kosenko**, General Director, Scientific Center for Expertise of Medicinal Products of the Ministry of the Ministry of Health of the Russian Federation
- **Natalya Manturova**, Head, Department of Plastic and Reconstructive Surgery, Cosmetology and Cell Technologies, Pirogov Russian National Research Medical University (RNRMU); Chief Temporary Plastic Surgeon, Ministry of Health of the Russian Federation
- **Irina Panarina**, General Manager, AstraZeneca Russia and Eurasia
- **Ekaterina Priezzheva**, Deputy Minister of Industry and Trade of the Russian Federation
- **Anastasia Stolkova**, First Deputy Chief Executive Officer for Development, Director of the Healthcare Directorate, Roscongress Foundation
- **Tatyana Yakovleva**, First Deputy Head, Federal Medical-Biological Agency of the Russian Federation

Front row participant:

- **Olga Postnikova**, Chief Executive Officer, Dobroe Delo Social Care Centre ANPO

14:30–16:00

Congress Centre
zone B, 2nd floor,
conference hall B2

'Ensuring Drug Security' Russian Pharmaceutical Forum**Made in Russia. How Can Domestic Pharmaceutical Products Win Over Consumer Trust?**

The success of Russia's goal to ensure its sustainable national drug sovereignty not only depends on the effectiveness of regulatory decisions, but also on the level of public confidence in domestic drugs. The strategies for improving the reputation of the Russian pharmaceutical industry should be based on constructive interaction between government, business, and the professional and scientific community in the public's interests. Russia needs sound communication strategies based on the principles of information openness among all institutions involved in this process, a well-reasoned and consistent dialogue, a solid body of evidence, and the high quality and safety profile of domestic medicines. In terms of the information and awareness agenda, we need to create open platforms for cooperation that representatives of the medical community will be able to use to visit pharmaceutical enterprises and learn first-hand about the results of advanced technologies and developments, drug effectiveness indicators, and the quality assurance system in manufacturing in order to become ambassadors of Russian pharmaceutical products for the patient community. What trust factors influence the image of Russian pharmaceutical products and how should we manage them? Which institutions should represent the interests of the Russian pharmaceutical industry in the face of public opinion and what is the best way to involve them in this process? What effective tools can destroy stereotypes in society's attitude towards domestic drugs and help increase public confidence in Russian medicines?

Moderator:

- **Aleksandr Petrov**, Deputy, member of the State Duma Committee on Health Protection of the Federal Assembly of the Russian Federation

Panellists:

- **Denis Chetverikov**, President, AKRIKHIN

- **Victor Dmitriev**, General Manager, Association of Russian Pharmaceutical Manufacturers; Chairman of the Public Council under the Federal Service for Surveillance in Healthcare
- **Vasily Ignatiev**, General Director, R-Pharm
- **Guzeliya Imaeva**, Chief Executive Officer, NAFI Research Centre
- **Oxsana Pozdnyakova**, General Director, Nizhpharm
- **Svetlana Semecheva**, Deputy Director, Department of Pharmaceutical Provision and Regulation of the Circulation of Medical Devices, Ministry of Health of the Russian Federation (**online**)
- **Evgeniya Shapiro**, Director General, PSK Pharma
- **Vladislav Shestakov**, Director, State Institute of Drugs and Good Practices

Front row participants:

- **Valentina Kosenko**, General Director, Scientific Center for Expertise of Medicinal Products of the Ministry of the Ministry of Health of the Russian Federation
- **Marina Rykova**, Director of Strategic Marketing, GEROPHARM

14:30–16:00Congress Centre
zone B, 2nd floor,
conference hall B3

'Ensuring Drug Security' Russian Pharmaceutical Forum

Food as Medicine

In partnership with EFKO

Despite the wide variety and apparent abundance of modern products, accessibility to healthy food remains a global challenge. The UN estimates that more than three billion people do not have access to a healthy diet, and more than a billion are obese. Over the past 30 years, the number of adults with this diagnosis has doubled, while the incidence among children has quadrupled. The high cost of healthy food and people's lack of awareness about truly healthy or harmful eating habits have drastically shifted the focus of mass consumer demand towards products that provide a basic supply of energy, but cause deficiencies in vital nutrients and vitamins. Various estimates indicate that it will cost the world more than USD 30 billion from 2010 to 2030 to treat excess weight and related chronic non-communicable diseases. It is crucial for major companies in the food industry, science, and the government to jointly create a healthy food market and join forces to reduce the spread of socially significant diseases. Such collaboration should result in the creation of mechanisms to stimulate the development of innovative products, tools to make balanced diets more accessible and monitor the quality and safety of food in all price categories, as well as programmes that help increase public awareness about ways to preserve people's health, develop healthy eating habits, and boost consumer demand for healthy food. How does modern science define healthy food and a balanced diet? What innovations in the food industry aim to provide people with high-quality, nutritious, and healthy products? What forms and methods of interaction between the government, science, and business could help expand the size of the healthy food market and ensure people have access to a healthy diet? How can we promote good eating habits among the population? How can food help humans remain competitive with artificial intelligence? Is it possible to ensure the mass availability of healthy food on the market instead of it being available to just a select few? Can healthy food help enhance human resourcefulness?

Moderator:

- **Sergey Ivanov**, Executive Director, Member of the Board of Directors, EFKO Management Company

Panellists:

- **Dmitry Alekseev**, Associate Professor, North Caucasus Federal University
- **Anastasia Badaeva**, Neurologist; Coordinator of Neuronutritional Sciences, Association for Interdisciplinary Medicine; Assistant of the Department of Pathological Physiology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
- **Vyacheslav Dubynin**, Professor, Department of Human and Animal Physiology, Faculty of Biology, Lomonosov Moscow State University
- **Julius Oben**, Professor of Nutritional Biochemistry, University of Yaounde
- **Xingyun Peng**, Associate Professor, College of Food Science and Nutritional Engineering, China Agricultural University

14:30–16:00Congress Centre
zone D, conference hall
D4

'Ensuring Drug Security' Russian Pharmaceutical Forum

Rare Diseases. Innovative Approaches to Therapy and Patient Care and the Establishment of Domestic Orphan Drug Production

Orphan diseases are a heavy medical and social burden for any state. Roughly 70% of orphan diseases are genetic, progressive, and lead to either disability or early mortality. Moreover, the rarity of such diseases is what causes problems with their diagnosis. Insufficient data about them prevents us from determining their prevalence and, as such, does not provide pharmaceutical companies with the opportunity to forecast the potential market and the efficiency of investments. Some countries struggle to conduct local clinical trials due to their low number of patients with orphan diseases. These factors

limit the ability to provide drugs to patients with orphan diseases. To expand such opportunities and jumpstart the market for innovative orphan drugs, it is crucial to strengthen tools for international cooperation, from developing therapies, conducting full-scale clinical studies, collecting and analysing data from real clinical practice, and creating common registries, to consolidating demand and developing mechanisms for joint international procurements. Given the economic sanctions in Russia, the problem of access to innovative pharmaceutical technologies must be solved by improving national technological sovereignty. How can we ensure the creation of domestic developments for molecular genetic research into orphan diseases? How can we promote the creation of patient registries? What regulatory and financial practices could stimulate the development of innovative orphan drugs? How can we ensure the availability of orphan drugs, including for adult patients? What effective tools to support the provision of orphan drugs can be borrowed from international experience?

Moderators:

- **Sergey Kutsev**, Director, Academician N.P. Bochkov Medical Genetic Research Center; Chief Freelance Specialist in Medical Genetics of the Ministry of Health of Russia
- **Tatyana Pervunina**, Director of the Institute of Perinatology and Pediatrics, V.A. Almazov National Medical Research Center of the Ministry of Health of the Russian Federation

Panellists:

- **Oleg Ergashev**, Vice-Governor of Saint Petersburg
- **Dmitriy Galkin**, Director of Department of Pharmaceutical and Medical Industry Development, Ministry of Industry and Trade of the Russian Federation
- **Guvenc Kockaya**, General Director, Econix Research, Analysis and Consulting Inc.
- **Igor Korobko**, Head of Science and Innovative Development of Health Department, Ministry of Health of the Russian Federation (**online**)
- **Elena Maksimkina**, Director, Federal Center for Planning and Regulation of Medical Supply Circulation of the Ministry of Health of the Russian Federation
- **Inga Nizharadze**, General Director, Skopinpharm
- **Vitaliy Omelyanovskiy**, General Director, Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation
- **Aleksandr Tkachenko**, Archipiest; Chairman of the Committee of Charity and Social Work of the Civic Chamber of the Russian Federation; Chairman of the Board, Circle of Kindness Foundation
- **Yury Zhulev**, President, Russian Hemophilia Society

Front row participant:

- **Alexey Kosolapov**, Commercial Director, Alexion Pharmaceuticals

14:30–16:30

Hilton St. Petersburg
ExpoForum, 2nd floor
Hilton Hall 1

'Ensuring Drug Security' Russian Pharmaceutical Forum

Round Table for BRICS Regulators of Medical Products

(by invitation)

16:45–18:15

Congress Centre
zone B, 2nd floor,
conference hall B1

'Ensuring Drug Security' Russian Pharmaceutical Forum

Genetics: A Key to New Opportunities in Protecting Health

Genetics are currently one of the key tools for a personalized approach to the provision of medical care, ranging from more precise primary measures to prevent and diagnose diseases to effective, efficient treatment based on a person's individual genetic characteristics, as well as the creation of innovative medicines. The scope of genetic research is growing in Russia and throughout the world each year. At the same time, due to greater competition from domestic and foreign market players, the cost of such research is naturally decreasing, while the state is offering more and more support measures to develop this promising area. However, the regulation of genetic technologies cannot currently keep pace with the rapid development of the industry and the intense growth rates seen on the global market. In what sectors are genetics most widely used today? What scope of genetic research is projected for the next decade? What is stimulating and can further jumpstart this growth? Are government support measures sufficient, and what is the role of private business in this regard? What can we change in regulatory documents to make regulation strict but fair? What is genetic certification and how will it affect the market for genetic technologies? How profitable is it to invest in genetic technologies today?

Moderator:

- **Marina Kaznarova**, Development Director, International Medical Cluster Foundation, Deputy Director of the Institute for the Training of Medical Education Specialists of the Federal State Budgetary Educational Institution of Further Professional Education RMANPE of the Ministry of Health of Russia

Panellists:

- **Irina Alekseenko**, Deputy General Director for Science, Moscow Center for Innovative Technologies

- **Dmitry Artyukhov**, Governor of Yamalo-Nenets Autonomous Region
- **Vladislav Bezrukov**, Deputy General Director for Research, ArchiMed Clinic of New Medical Technologies LLC
- **Oksana Drapkina**, Director, National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
- **Julia Dyakova**, First Deputy Director for Science, "Kurchatov Institute" National Research Center
- **Oleg Grin**, Director, Scientific and Educational Center for Law and Bioethics in the Field of Genomic Research and Application of Genetic Technologies, Kutafin Moscow State Law University (MSAL)
- **Alexander Kharkchinov**, Deputy General Director, Evogen
- **Anna Kostareva**, Director, Federal State Budgetary Institution "National Medical Research Center named after. V. A. Almazov" of the Ministry of Health of Russia;
- **Sergey Kutsev**, Director, Academician N.P. Bochkov Medical Genetic Research Center; Chief Freelance Specialist in Medical Genetics of the Ministry of Health of Russia
- **Dmitry Trofimov**, Director, Institute of Reproductive Genetics, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation (**online**)
- **Irina Zabolotnaya**, Deputy Director of the Department of Social Policy, Norilsk Nickel

16:45–18:30

Hilton St. Petersburg
ExpoForum, 2nd floor
Hilton Hall 1

'Ensuring Drug Security' Russian Pharmaceutical Forum

BRICS Health Regulatory Agencies Meeting

(by invitation)

16:45–18:15

Congress Centre
zone B, 2nd floor,
conference hall B2

'Ensuring Drug Security' Russian Pharmaceutical Forum

Medicine of the Future: Biomedical Technologies to Create New Drugs

Medicine is constantly evolving and progressing, and one of the main components of this progress is biomedical technologies, which offer new possibilities for the creation of drugs that effectively combat various diseases. One of the key breakthroughs in modern medicine has been the development of personalized medicines. Biomarkers that are unique to individual patients or groups of patients enable physicians to administer the appropriate medications to achieve the best possible results. A key focus is the study of the human genome. Using modern DNA sequencing methods, scientists have managed to decipher the entire genome. This has made it possible to create individual medicines, taking into account a person's genetic characteristics and predisposition to certain diseases. With the development of artificial intelligence, biomedical technologies are becoming even more advanced. Algorithms can analyse large volumes of data about diseases and clinical trial results, which helps scientists create new, more effective drugs. Biomedical technologies are contributing to the creation of new drugs. Personalized medicine, the use of stem cells, and advanced imaging techniques are providing more effective, precise, and minimally invasive treatments for various diseases. As biomedical technologies continue to advance, we can expect major advances in the development of medicines that will improve the health and well-being of people around the world. Which areas of high technology are the most promising and rapidly developing in global medical science? What innovative drugs for the treatment of socially significant diseases have been put into clinical practice today? What will help increase the availability of high-tech medical care to the population?

Moderator:

- **Igor Borisevich**, Deputy Head, Federal Medical-Biological Agency of the Russian Federation

Panellists:

- **Badma Bashankaev**, Deputy of the State Duma of the Federal Assembly of the Russian Federation; Member of the State Duma Committee on Health Protection
- **Musa Khaitov**, Director, National Research Center – Institute of Immunology of the FMBA of Russia
- **Konstantin Kotenko**, Director, Academician B.V. Petrovsky Russian Scientific Center of Surgery
- **Sergei Lukyanov**, Rector, N.I. Pirogov Russian National Research Medical University
- **Alexey Lundup**, Director of the Scientific and Educational Resource Center for Cellular Technologies, Patrice Lumumba Peoples' Friendship University of Russia
- **Ekaterina Priezzheva**, Deputy Minister of Industry and Trade of the Russian Federation
- **Sevastian Rabdano**, Deputy Director for Development of New Medicines, Federal State Unitary Enterprise SPbNIIVS of the FMBA of Russia

16:45–18:15

Congress Centre
zone A, 3rd floor,
conference hall A

'Ensuring Drug Security' Russian Pharmaceutical Forum

Safe Beauty: How to Combine the Affordability and Quality of Aesthetic Injection Drugs

Aesthetic medicine is a rapidly developing industry that offers various methods to correct a person's external appearance, with injection cosmetology playing a key role. The active growth of this market is being driven by the growing public demand for 'beauty injections' each year and the fact that Russia has a clear regulatory framework governing the aesthetic medicine industry. The number of clinics and skilled professionals that provide cosmetology services is on the rise. New drugs and innovative techniques are appearing on the market. However, regulating and improving these development processes along with monitoring the safety and effectiveness as well as the import and distribution of injectable drugs and consumables remains a crucial task for the government in order to protect citizens and further develop the industry. While imports are undergoing changes and foreign injectable cosmetics that are already familiar and proven among consumers are being replaced by lesser-known drugs from new supplying countries, there are a sufficient number of effective and safe domestic analogues on the market that have prospects to fill this vacated niche. How can we combine the availability, quality, and effectiveness of cosmetic injection drugs produced domestically and abroad in this changing market? What measures are currently in place to fundamentally transform the aesthetic medicine and injection cosmetology industry? What domestic developments and existing drugs for aesthetic injection medicine have the greatest potential for use in Russia and abroad?

Moderator:

- **Anna Dycheva-Smirnova**, Managing Director, EXPOVISIONRUS; organizer, InterCHARM

Panellists:

- **Elena Dobroserdova**, Deputy Director for Marketing and Sales, AxelPharm and Ingal
- **Elena Ebadi**, Anti-age journalist; Founder, ProBeauty Agency
- **Irina Filatova**, Member of the Committee State Duma of the Federal Assembly of the Russian Federation on Competition Committee
- **Madina Magomedova**, Founder, Chief Physician, Anti-Aging Medical Clinic, Dermavi
- **Natalya Manturova**, Head, Department of Plastic and Reconstructive Surgery, Cosmetology and Cell Technologies, Pirogov Russian National Research Medical University (RNRMU); Chief Temporary Plastic Surgeon, Ministry of Health of the Russian Federation
- **Ilya Platonov**, Director of Cosmetology Promotion, Solopharm
- **Irina Shapiro**, Founder, Omny Beauty Clinic
- **Ekaterina Vasilyeva**, Founder, Artleo Clinic

Front row participants:

- **Anna**, Dentist, Orthodontist, PRODENT Dentistry
- **Ekaterina Shostak**, Dermatologist, Cosmetologist, Head of the Cosmetology Department, DEGA

16:45–18:15

Congress Centre
zone B, 2nd floor,
conference hall B4

'Ensuring Drug Security' Russian Pharmaceutical Forum

Preventive Medicine: Prevention or Treatment?

Preventive medicine is a new healthcare paradigm based on preventing diseases and maintaining active longevity. Measures for the early detection of diseases and the risk factors that cause them, predicting the onset of serious health problems long before their first signs appear, personalized health support programmes, and lifestyle adjustments to strengthen healthy habits are all basic aspects of a preventive approach that aims to improve people's quality of life and extend healthy life expectancy. An integrated approach is applied in modern clinical preventive practices based on the use of both medicinal and scientifically proven non-medicinal methods of disease prevention. New technologies to prevent the development of dangerous age-related diseases and promote health, which are based on an individual approach and the principle of understanding the body as an integral system, help to preserve its functional state for the long term, prevent the onset of diseases or delay it as much as possible, and increase life expectancy. Preventive medicine is a sound economic investment that makes it possible to provide medical care well in advance, which can reduce the need for more costly treatment later. What achievements in preventive medicine and innovative diagnostics are protecting people's health today? How is the transition to preventive medicine impacting the drug market? How ready are the professional and patient communities, the government, and the pharmaceutical business today for the transition to a preventive healthcare model?

Moderator:

- **Aleksandra Ulich**, Chief Executive Officer, Kivach Clinic

Panellists:

- **Anna Abramovich**, General Practitioner, Medical Organizer
- **Sergey Chudakov**, Chairman of the Board, Association of General Practitioners (Family Doctors) of the Moscow Region; Head, National Standards of Prevention Research Project

- **Marina Kurganova**, Director, National Agency for the Development of Social Initiatives
- **Irina Liberman**, Deputy General Director, Medscan Group; Head of Medicine Business Unit
- **Olga Moroz**, Founder of the clinic of aesthetic medicine by Olga Moroz
- **Olga Tkacheva**, Director of the Russian Gerontological Research and Clinical Center, Research Institute of Translational Medicine, N.I. Pirogov Russian National Research Medical University; Chief Freelance Specialist Geriatrician of the Ministry of Health of the Russian Federation